NRG-GI007: Phase 1 Study of OBP-301, An Oncolytic Virus, and Definitive Chemoradiation in Locally Advanced Esophageal Cancer
Geoffrey Y Ku(Memorial Sloan Kettering Cancer Center), Terence M Williams(City of Hope), Jessica M. Frakes(Moffitt Cancer Center), Talia Biran(Oncolys BioPharma (Japan)), Prasad S. Adusumilli(Memorial Sloan Kettering Cancer Center), Jennifer Moughan(NRG Oncology), Eric D. Miller(The Ohio State University), Rutika Mehta(University of Indianapolis), Makoto Nishimura(Memorial Sloan Kettering Cancer Center), Samuel J. Klempner(Broad Institute), Kathryn Winter(The University of Texas MD Anderson Cancer Center), David Ilson(Memorial Sloan Kettering Cancer Center), Abraham Wu(Memorial Sloan Kettering Cancer Center), Theodore S. Hong(Massachusetts General Hospital), Adam D. Yock(Vanderbilt University Medical Center)
Cited by 0
Related Papers
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
|Journal of Clinical Investigation|2016|1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
|Cancer Discovery|2021|551